# Envoy Medical, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Envoy Medical, Inc.). ## Overview Envoy Medical, Inc. develops and commercializes implantable hearing devices, with current revenue coming primarily from the Esteem FI-AMEI fully implanted active middle ear implant and related replacement components. The company is also advancing its Acclaim CI cochlear implant program, which is still in clinical development and targeted for future FDA approval and commercialization. ## Products & services • Esteem FI-AMEI fully implanted active middle ear implant • Replacement sound processor / battery assemblies • Personal programmer devices • Optional Care Plan services • Acclaim CI cochlear implant development program - **Commercial hearing implants** (90%) — Sales of the Esteem FI-AMEI implant system and related replacement components used in implanted patients. - **Replacement and consumables** (10%) — Battery/sound processor replacements and other recurring post-implant components for existing patients. - **Clinical development programs** (0%) — R&D work for the Acclaim CI cochlear implant and continued support for the Esteem platform. - Esteem FI-AMEI fully implanted active middle ear implant - Replacement sound processor / battery assemblies - Personal programmer devices - Optional Care Plan services - Acclaim CI cochlear implant development program ## Customers Envoy Medical sells to patients and the clinical providers who implant and manage its hearing devices, with reimbursement and surgical adoption being central to demand. Current revenue is driven by a very small installed base of Esteem FI-AMEI patients, while future growth depends on successful clinical trial execution and eventual commercialization of Acclaim CI. - **Implant patients** (primary) — Patients who receive the Esteem FI-AMEI device and later buy replacement components or services. - **Surgical providers** (primary) — ENT surgeons, hospitals, and clinical centers that implant and support the devices. - **Payers and reimbursement stakeholders** (primary) — Insurers and coverage authorities that determine whether patients can access the devices economically. - **Future cochlear implant market** (emerging) — Potential Acclaim CI customers if the product receives FDA approval and reaches commercialization. - Patients receiving the Esteem FI-AMEI implant system - Hospitals and surgeons performing implantation procedures - Existing implant patients needing battery/sound processor replacements - Patients and clinicians considering future Acclaim CI adoption - Payers and reimbursement decision-makers influence access and uptake ## Geography The company is headquartered in the United States and its current commercial activity is centered on the U.S. market. Its near-term operating footprint is also U.S.-based because clinical development, FDA interactions, and reimbursement efforts are the main drivers of the business. - Headquartered in the United States - Commercial activity is currently centered in the U.S. - FDA clinical development and approval process is U.S.-based - Reimbursement strategy is focused on U.S. coverage decisions - No country-level revenue disclosure was provided in the excerpts ## Strategy Envoy Medical is focused on extending the life of its current implant franchise while advancing Acclaim CI through staged clinical trials and toward PMA submission. A major strategic priority is securing favorable reimbursement and regulatory outcomes, since both are necessary to expand adoption beyond the small current installed base. - **Complete Acclaim CI clinical development** (medium-term) — The product is the main future growth driver and requires successful trial execution before PMA filing. - **Secure FDA approval and commercialization readiness** (medium-term) — Regulatory clearance is required before Acclaim CI can generate meaningful revenue. - **Improve reimbursement coverage** (short-term) — Coverage changes could materially expand patient access and implant volumes. - **Maintain liquidity and fund operations** (short-term) — The company is loss-making and depends on external financing to support trials and operations. - Advance Acclaim CI through staged clinical trials - Target FDA approval and PMA submission for Acclaim CI - Pursue reimbursement changes for fully implanted hearing devices - Support the installed Esteem base with replacement components - Raise capital to fund R&D, trials, and commercialization ## Risks Envoy Medical faces substantial execution risk because it is still funding clinical development and has a limited commercial base. Its business is also exposed to regulatory timing, reimbursement uncertainty, and financing needs, all of which can materially affect the pace of product adoption and the company’s ability to continue operations. - **Regulatory and clinical development delay** [high] — Acclaim CI must complete staged trials and PMA review before commercialization, so any delay pushes out revenue and increases cash burn. - **Reimbursement and coverage risk** [high] — The company explicitly relies on positive reimbursement changes to expand implant volumes and patient access. - **Liquidity and financing risk** [high] — The company has incurred significant operating losses and has funded operations primarily through equity and debt financing. - **Commercial concentration risk** [medium] — Current revenue comes substantially all from a single product family and a very small number of implant events. - **Inventory and manufacturing risk** [medium] — The company carries excess/obsolete inventory reserves and write-offs, which can rise if demand remains low or product mix changes. - Clinical trial delays could push out Acclaim CI approval and revenue - Reimbursement uncertainty limits adoption of fully implanted devices - Small installed base creates concentration in a few implant and replacement sales - Ongoing losses increase dependence on external financing - Manufacturing and inventory risks can affect gross margin and write-offs ## Accounting Revenue is recognized at a point in time when the company is notified that the device has been implanted or used in surgery, so reported sales depend on implantation timing rather than shipment alone. Because the business is early-stage and loss-making, estimates around inventory reserves, fair value measurements, stock-based compensation, and financing-related interest can have a noticeable effect on reported results. - **Point-in-time revenue recognition** — Can shift revenue between quarters and make trends lumpy - **Inventory reserves and write-offs** — Affects gross margin and operating loss - **Fair value measurements** — Can create non-cash gains or losses - **Stock-based compensation** — Raises operating expenses without immediate cash outflow - **Interest expense on related-party and financing arrangements** — Can materially change reported bottom-line results - Revenue is recognized when implantation/use is confirmed - Small implant volumes can create quarter-to-quarter volatility - Inventory reserves and write-offs affect cost of goods sold - Fair value estimates matter for financing instruments - Stock-based compensation is a meaningful non-cash expense --- *Last updated: 2026-04-28T20:05:14.738955+00:00*